Irrmischer Mona, Puxty Drew, Yıldırım Barış Onur, Deijen Jan Berend, Engelbregt Hessel
GGZ Research, Hersencentrum Mental Health Institute, Amsterdam, The Netherlands.
PsyInternational Therapy, Utrecht, The Netherlands.
Psychopharmacology (Berl). 2025 Apr;242(4):725-740. doi: 10.1007/s00213-024-06733-3. Epub 2025 Jan 7.
Psychedelic-assisted therapy is increasingly applied within mental health treatment.
This study focused on factors moderating changes in the acute and long-term effects of an individual psilocybin-assisted program on depression, anxiety, PTSD and personality structures by including demographic factors, subjective experience and degree of mystical type experiences during the dosing, as well as emotional breakthrough and personal growth after the program.
At baseline, 1 week and 3 months after the psilocybin program participants completed the Generalized Anxiety Disorder Assessment (GAD-7), Patient Health Questionnaire (PHQ-9), PTSD Checklist for DSM-5 (PCL-5) and NEO Five-Factor Inventory-3 (NEO-FFI-3). In addition, after the dosing the Mystical Experiences Questionnaire (MEQ-30), Posttraumatic Growth Inventory (PTGI) and Emotional Breakthrough Inventory (EBI) were administered. Moderation effects were established using linear mixed-model analysis.
A single high dose of psilocybin in combination with therapy was found to lower symptoms of anxiety, depression, PTSD and neuroticism over a period of 3-months. Scores on openness and conscientiousness increased after the treatment only. Participants reported mystical type experiences, emotional breakthrough and personal growth. These subjective experiences together with demographic factors were moderating the observed positive changes.
Findings indicate that individual psilocybin-assisted therapy has the potential for beneficial effects on mood and personality characteristics. Moreover, the study highlights the importance of subjective experiences and demographic factors in moderating this effect. This study adds to the ongoing research on psilocybin-assisted therapy by investigating contributing factors for optimizing this evolving type of therapy.
迷幻剂辅助治疗在心理健康治疗中的应用日益广泛。
本研究聚焦于调节个体裸盖菇素辅助治疗方案对抑郁、焦虑、创伤后应激障碍（PTSD）和人格结构的急性及长期影响变化的因素，包括人口统计学因素、主观体验、给药期间的神秘主义体验程度，以及治疗后的情绪突破和个人成长。
在裸盖菇素治疗方案的基线、1周和3个月后，参与者完成广泛性焦虑障碍评估（GAD - 7）、患者健康问卷（PHQ - 9）、DSM - 5创伤后应激障碍检查表（PCL - 5）和NEO五因素问卷 - 3（NEO - FFI - 3）。此外，给药后进行神秘主义体验问卷（MEQ - 30）、创伤后成长量表（PTGI）和情绪突破量表（EBI）的评估。使用线性混合模型分析确定调节效应。
发现单次高剂量裸盖菇素联合治疗在3个月内可降低焦虑、抑郁、PTSD和神经质症状。仅在治疗后开放性和尽责性得分有所提高。参与者报告了神秘主义体验、情绪突破和个人成长。这些主观体验以及人口统计学因素调节了观察到的积极变化。
研究结果表明，个体裸盖菇素辅助治疗对情绪和人格特征具有潜在的有益影响。此外，该研究强调了主观体验和人口统计学因素在调节这种效应方面的重要性。本研究通过调查优化这种不断发展的治疗类型的影响因素，为正在进行的裸盖菇素辅助治疗研究增添了内容。
